← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2015Last known activity
Nov 18, 2024
Timeline
2010s
- Jun 1, 2015
Ozmosis Research Inc.— Founded
Drugs by trial phase (25 distinct, 22 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (17 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Breast Neoplasms
- Carcinoma
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Fabry Disease
- Fallopian Tube Neoplasms
- Graft vs Host Disease
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma
- Lymphoma, Non-Hodgkin
- Myelodysplastic Syndromes
- Neoplasms
- Preleukemia
- Prostatic Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- Rectal Neoplasms
- Urinary Bladder Neoplasms
Recent trials (22)
- NCT06693336CollaboratorPhase 2Nov 18, 2024
- NCT06650709CollaboratorPhase 2Nov 1, 2024
- NCT06613217CollaboratorPhase 1Oct 31, 2024
- NCT06331455CollaboratorPhase 2May 22, 2024
- NCT05848713CollaboratorPhase 3Oct 10, 2023
- NCT04836195CollaboratorPhase 1Sep 14, 2021
- NCT04944173CollaboratorPhase 2Jun 30, 2021
- NCT04543110CollaboratorPhase 2Sep 30, 2020
- NCT04202835CollaboratorPhase 2Feb 1, 2020
- NCT03283943CollaboratorPhase 1Apr 1, 2018
- NCT02750670CollaboratorPhase 2Mar 15, 2017
- NCT03027102CollaboratorPhase 1Mar 1, 2017
- NCT02599779CollaboratorPhase 2Dec 1, 2016
- NCT02743741CollaboratorN/AJul 1, 2016
- NCT02800070CollaboratorPhase 1Jul 1, 2016
Details
- Founded
- Toronto, CA Jun 1, 2015
- Last known activity
- Nov 18, 2024
Notes
CRO